Core Viewpoint - Elutia Inc. has been certified as a Great Place to Work®, highlighting its high-trust workplace culture and commitment to employee engagement and retention in the innovation-driven medical industry [1][6]. Company Overview - Elutia develops and commercializes drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients, with a mission to humanize medicine [8]. - The company has a strong focus on creating first-in-class products and maintaining disciplined regulatory execution, which is essential for its mission [5]. Workforce and Culture - Elutia's workforce is characterized by a commitment to excellence, with 54% of employees being women and 62% of leadership roles held by women [3]. - The company boasts a median employee tenure of 6.3 years, indicating stability and continuity within the organization [3]. - Half of Elutia's team members hold advanced degrees, and one-third hold doctorates, reflecting a highly educated workforce [3]. Leadership Insights - Leadership emphasizes the importance of clarity and discipline in execution, which contributes to a productive and innovative work environment [4]. - The company’s culture is described as demanding yet rewarding, attracting individuals who want their work to have a significant impact [2][5]. Certification Significance - The Great Place to Work® certification is based on employee feedback regarding workplace experience, and it is recognized globally as a benchmark for outstanding employee experience [9][10]. - Organizations with this certification typically experience 50% lower turnover rates and outperform industry benchmarks in performance [6].

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 18, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a Letter Agreement (the "Agreement") with a business group ("BG") to establish an entity named Izotropic Afric ...

The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof. Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions, and estimates and are not intended to be a guarantee ...

Core Insights - Insulet reported better-than-expected fourth-quarter results driven by strong demand for its tubeless insulin pumps, forecasting 20% to 22% revenue growth for full-year 2026 in constant currency and over 25% increase in adjusted earnings per share [1] Financial Performance - Insulet's sales for the fourth quarter reached $781.8 million, exceeding analysts' estimates of $767.3 million, with total revenue jumping 31.2% to $783.8 million compared to estimates of $768.7 million [1] - On an adjusted basis, Insulet earned $1.55 per share for the quarter, surpassing estimates of $1.45 [1] Future Outlook - For the current quarter, Insulet forecasts revenue growth of 25% to 27% in constant currency [1] - The company announced a $350 million increase to its share repurchase authorization, planning to deploy approximately $300 million in buybacks during the first quarter of 2026, which analysts view as a bullish signal [1] Product Demand - Insulet's sales surge is attributed to broader regulatory approvals for its Omnipod 5 automated insulin delivery system, now cleared for use in both type 1 and type 2 diabetes patients in the U.S. [1] - The demand for Insulet's products aligns with similar trends observed in the market, as its larger peer Dexcom also reported robust demand for continuous glucose monitoring systems [1]

The Cooper Companies (COO), headquartered in San Ramon, California, develops, manufactures, and markets contact lens wearers. Valued at $16.3 billion by market cap, the company’s products include contact lenses for the vision care market and diagnostic products, surgical instruments, and accessories for gynecologists and obstetricians. Shares of this global medical device company have underperformed the broader market over the past year. COO has declined 7% over this time frame, while the broader S&P 500 ...

Tactile Systems reported fourth-quarter earnings of 46 cents, better than the consensus of 44 cents. Sales jumped 21% to $103.59 million, beating the Wall Street estimates of $93.80 million, attributable to lymphedema and airway clearance product lines.Tactile Systems forecasts fiscal 2026 sales between $357 million-$365 million compared to the consensus of $347.94 million. The company expects adjusted EBITDA in the range of $49 million to $51 million.Tactile Systems shares fell 5.3% to close at $283.46 on ...

Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Valued at a market capitalization of $17.1 billion, the company offers the Omnipod platform, comprising the Omnipod 5 automated insulin delivery system and the Omnipod DASH insulin management system. The company's shares have underperformed the broader market over the past year and in 2026. PODD stock has decl ...

AcuityMD Announces AcuityMD for Salesforce on Salesforce AppExchangeFeb 18, 2026 7:05 AM Eastern Standard Time# AcuityMD Announces AcuityMD for Salesforce on Salesforce AppExchangeShare--- AcuityMD's customers can now benefit from a Salesforce integration that unifies market intelligence and rep-centric workflowsBOSTON--([BUSINESS WIRE])--AcuityMD today announced it has launched AcuityMD for Salesforce on Salesforce AppExchange, the leading enterprise marketplace for partner apps and experts, empowering cus ...

Investor presentation February 18, 2026 Chloe Podder since 2021 The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof. Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, a ...

We recently published 10 Stocks Outperforming With Monstrous Gains. Masimo Corporation (NASDAQ:MASI) was one of the best performers on Tuesday. Masimo Corp. snapped a two-day losing streak on Tuesday, soaring 34.22 percent to finish at $174.69 apiece as investors snapped up shares following news that it was set to merge with Danaher Corp. for $9.9 billion. In a statement, Masimo Corporation (NASDAQ:MASI) said that it officially inked a definitive agreement with Danaher for the acquisition of its shares ...